A new trading day began on Monday, with Seelos Therapeutics Inc (NASDAQ: SEEL) stock price down -13.37% from the previous day of trading, before settling in for the closing price of $0.43. SEEL’s price has ranged from $0.22 to $300.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -20.00% annually for the last half of the decade. With a float of $5.65 million, this company’s outstanding shares have now reached $5.96 million.
In an organization with 16 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 97.07%, operating margin of -1480.04%, and the pretax margin is 203.13%.
Seelos Therapeutics Inc (SEEL) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Seelos Therapeutics Inc is 5.20%, while institutional ownership is 3.58%. The most recent insider transaction that took place on Nov 30 ’23, was worth 100,222. In this transaction Chief Financial Officer of this company bought 83,000 shares at a rate of $1.21, taking the stock ownership to the 86,450 shares. Before that another transaction happened on Dec 01 ’23, when Company’s See Remarks bought 75,757 for $1.32, making the entire transaction worth $99,999. This insider now owns 185,142 shares in total.
Seelos Therapeutics Inc (SEEL) Performance Highlights and Predictions
In its latest quarterly report, released on 12/31/2023, the company reported earnings of -28.8 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
Seelos Therapeutics Inc (NASDAQ: SEEL) Trading Performance Indicators
Here are Seelos Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 0.08. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.11.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 11.04
Technical Analysis of Seelos Therapeutics Inc (SEEL)
Let’s dig in a bit further. During the last 5-days, its volume was 16.53 million. That was better than the volume of 0.78 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 70.26%. Additionally, its Average True Range was 0.08.
During the past 100 days, Seelos Therapeutics Inc’s (SEEL) raw stochastic average was set at 2.91%, which indicates a significant decrease from 63.61% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 242.34% in the past 14 days, which was higher than the 142.36% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5553, while its 200-day Moving Average is $7.8561. However, in the short run, Seelos Therapeutics Inc’s stock first resistance to watch stands at $0.4144. Second resistance stands at $0.4557. The third major resistance level sits at $0.5226. If the price goes on to break the first support level at $0.3062, it is likely to go to the next support level at $0.2393. Assuming the price breaks the second support level, the third support level stands at $0.1980.
Seelos Therapeutics Inc (NASDAQ: SEEL) Key Stats
With a market capitalization of 2.22 million, the company has a total of 2,173K Shares Outstanding. Currently, annual sales are 2,200 K while annual income is -37,880 K. The company’s previous quarter sales were 580 K while its latest quarter income was -2,660 K.
